Full Breakdown
BioNTech Founders Depart to Launch New mRNA Venture
3/10/2026, 8:12:11 PM
Leadership Transition at BioNTech
Ugur Sahin, M.D., and Özlem Türeci, M.D., co-founders of BioNTech, will leave the company by the end of 2026 to establish a new biotechnology firm focused on next-generation mRNA innovations. This decision marks a significant shift for BioNTech, which gained prominence through its partnership with Pfizer to develop the COVID-19 vaccine, Comirnaty. The new venture will operate independently, utilizing mRNA technology from BioNTech, which will retain a minority stake and receive milestone payments and royalties from the new company.
Impact on BioNTech's Future
The announcement of the founders' departure has raised concerns among investors, leading to a sharp decline in BioNTech's stock price, which fell nearly 20% following the news. Analysts from Leerink Partners described the transition as a “logical step” for BioNTech as it matures into a multi-product company focused on oncology therapies. However, they also noted that the exit of the founding duo injects uncertainty into the company's future, particularly as it navigates a portfolio of late-stage oncology assets.
BioNTech's current pipeline includes several promising candidates, such as trastuzumab pamirtecan, an HER2-targeted antibody-drug conjugate, and an anti-CTLA-4 antibody called gotistobart. Despite the leadership change, the company has stated that its ongoing drug development efforts will remain unaffected.
Financial Context
BioNTech reported a net loss of €1.14 billion ($1.33 billion) for the previous year, a significant increase from a loss of €665 million in 2024. The company’s revenue projections for 2026 are between €2 billion and €2.3 billion, falling short of analyst expectations of €2.75 billion. This decline is attributed to decreasing demand for COVID-19 vaccines in the U.S. and Europe, which is expected to continue impacting revenue.
Criticism & Concerns
Critics have expressed concerns regarding the potential loss of scientific leadership and innovation that Sahin and Türeci provided. The market's reaction indicates a fear that BioNTech may struggle to maintain its competitive edge in the rapidly evolving biotech landscape without its founding visionaries. The uncertainty surrounding the leadership transition has led to questions about the company's long-term strategy and ability to execute its oncology-focused mission.
Official Statements & Responses
In a statement, Sahin emphasized the opportunity to "hand over the baton" and expressed readiness to "become pioneers once again." BioNTech's Supervisory Board Chairman, Helmut Jeggle, supported the founders' decision, stating that it allows them to focus on their strengths in a new venture while BioNTech continues to advance its late-stage product candidates.
What's Next for BioNTech
BioNTech is currently in the process of searching for new leadership to ensure a smooth transition. A binding agreement between BioNTech and the new company is expected to be finalized by the end of June 2026. As BioNTech aims to solidify its position as a multi-product company by 2030, the effectiveness of its strategy in the absence of its founders will be closely monitored by investors and analysts alike.
